**Sir**,

In a prospective cohort study of postmenopausal women with cancer ([@bib8]), it was found that current use of statins and other cholesterol-lowering medication was associated with lower risk of cancer deaths. However, a dose-response relationship was not found, thus suggesting that the improved survival in patients with cancer could in fact be related to the higher baseline cholesterol, which in turn led to cholesterol-lowering drug prescription.

Baseline total cholesterol concentration of statin-treated populations is often higher than those of the general population, especially in the primary prevention settings ([@bib7]). Of note, in the study by [@bib8], most of the enrolled women with current statin use (87%) had no coronary heart disease before cancer diagnosis.

Mounting evidence has established that low plasma levels of low-density lipoprotein cholesterol are associated with an increased risk of future cancer ([@bib2]). Furthermore, in a long-term follow-up study, moderate total serum cholesterol was found to have a protective effect on 40-year cancer mortality ([@bib5]), and an analysis of large statin randomised controlled trials demonstrated an inverse association between on-treatment low-density lipoprotein cholesterol levels and incident cancer ([@bib1]).

Increasing evidence has found that statins also exert their action beyond cholesterol reduction (pleiotropic effects), and a growing interest has been paid in their immunomodulatory effect, which may promote atherosclerotic plaque stability, but also hinder the host anti-tumour immune response, therefore, increasing cancer risk in certain segments of population ([@bib3]). In particular, it appears that statins increase the risk of cancer in the elderly, who are more likely to harbour cancer cells because of their advanced age and associated immunosenescence ([@bib4]). In the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER; [@bib6]), cancer incidence was increased significantly in subjects randomised to pravastatin over the 3.2-year study period. The mean age at trial entry was 75 years, and the decrease in cardiovascular disease mortality was offset by an equal increase in cancer mortality, resulting in unchanged overall mortality. Notably, the main age of postmenopausal statin users enrolled in the study by [@bib8] was only 63.6 years.

Therefore, although the protective effect of higher cholesterol levels on cancer risk may not completely represent an etiologic link, the study by [@bib8] suggests that current statin use might have selected the healthy statin user or unselected the unhealthy cancer patients with low cholesterol.
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